Tagged with Fact

Greece EY Greece’s George Mitropoulos outlines some of the key challenges and opportunities for both local manufacturers and multinational innovators in Greece, how EY is uniquely positioned to assist them, and the fundamentals that give him cause for optimism for both the Greek economy and its healthcare sector.   We believe…

Colombia Tecnoquímicas recently invested over USD 250 million in its Colombian manufacturing plants, signifying the company’s continuing faith in its home market. Executive Vice-President Emilio Sardi Aparicio outlines the regulatory and access landscape in Colombia today, how the firm’s international footprint within Latin America has evolved, and its approach to the…

Greece Evangelos Zekkas outlines Help Pharma’s internationalisation journey in recent years, with the Greek firm’s exports now accounting for 60 percent of production and 50 percent of turnover. Zekkas, the company’s long-serving president and managing director, also gives his thoughts on Greek pharma’s role in Europe post-COVID more broadly, the challenges…

Argentina Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful strategy predicated on customising its offering to each country and balancing local management autonomy with a strong company culture, as…

Brazil Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts, and the policy reforms he hopes that the country’s new administration will roll out.   The pandemic has given us…

Greece Speaking shortly after the unveiling of a EUR 55 million investment in a new factory in Keratea as part of a wider EUR 155 million spend up to 2025, ELPEN’s Theodore Tryfon outlines the company’s ambitious expansion and diversification plans; his hopes for the future of essential medicine manufacturing in…

Europe The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain components, including manufacturing, to independent CDMOs. In Europe the CDMO market is expected to reach a revenue of nearly USD…

Global IFPMA Director General Thomas Cueni highlights the global innovative pharmaceutical industry’s five key priorities for ensuring better national and international healthcare responses to future pandemics, drawing on the lessons of COVID-19.   The international community is working to rebuild the global health architecture to ensure it is fit for purpose…

South Africa Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as 70 to 90 percent of the medicines consumed there. As the COVID-19 pandemic further demonstrated this dependence and the vulnerability…

Egypt Barely four and a half years ago, Egyptian President Abdel Fattah el-Sisi secured overwhelming re-election vowing to “place public health front and centre” of a radical reform and stabilization agenda. What has occurred subsequently has undoubtedly been momentous. Firstly, his administration unveiled ambitious plans to provide universal, cradle to grave,…

Greece DEMO, founded in 1965, is a mainstay of Greek pharma and one of its largest companies, accounting for 25 percent of the total investment across the entire Greek pharmaceutical sector. Throughout its long history DEMO has shifted its focus, moved towards exports and weathered Greece’s financial crisis. Today, the family-owned…

Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos outlines his ambitious growth plan for the firm and…